VF
MLTX icon

Virtu Financial’s MoonLake Immunotherapeutics MLTX Stock Holding History

Virtu Financial’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$446K Buy
22,919
+12,393
+118% +$225K 0.01% 574
2026
Q1 		$196K Sell
10,526
-2,056
-16% -$34.1K 0.01% 1031
2025
Q4 		$166K Buy
+12,582
New +$148K 0.01% 1081
2023
Q1 		– Sell
-14,395
Closed -$151K – 1851
2022
Q4 		$151K Buy
+14,395
New +$128K 0.02% 814

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Virtu Financial's MLTX Position: Q2 2026 in Review

Virtu Financial increased its MoonLake Immunotherapeutics (MLTX) stake by 118% in Q2 2026, buying an estimated $225K and bringing the position to 22,919 shares worth $446K. The position accounts for 0.01% of the portfolio, ranked #574.

Virtu Financial first reported a position in MLTX in Q4 2022 and has held it in 4 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Virtu Financial held 22,919 shares of MoonLake Immunotherapeutics worth $446K as of Q2 2026.
  • Virtu Financial bought 12,393 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $225K.
  • MoonLake Immunotherapeutics made up 0.01% of Virtu Financial's portfolio in Q2 2026, its #574 holding.
  • Virtu Financial first reported a position in MoonLake Immunotherapeutics in Q4 2022 and has held it in 4 quarters since.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Virtu Financial's 13F filing for Q2 2026, filed 13 Aug 2026.